Publication | Open Access

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Hematological MalignancyOnce-per-week SelinexorMedicineHematologyMyeloid NeoplasiaMultiple MyelomaPharmacotherapyOncologyRadiation OncologyHealth Sciences